Drug maker Wyeth said on Tuesday that U.S. regulators canceled an advisory committee meeting to review the company's experimental drug for major depressive disorder.

According to Wyeth, the Food and Drug Administration decided it did not need the meeting in order to decide whether to approve the product, known as desvenlafaxine succinate extended release. The agency is expected to act by October.

"Wyeth is encouraged by this development and believes that its comprehensive clinical trials program for desvenlafaxine succinate supports the product's approval," the company said in a statement.

NEWS ARCHIVES

2008

• September
• August
• July
• June
• May
• April
• March

2007

• April
• March
• February
• January

2006

• December
• November
• October
• September
• August
• July
• June
• May
• April
• March
• February
• January

2005

• December
• November
• October
• August
• June
• April
• March
• February

2004

• December

NEWSLETTER SIGNUP